Engaging Patients to Optimize Outcomes in Gastroesophageal Reflux Disease
Premiere Date: Monday, June 15, 2015This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, June 15, 2016
Note: Credit Is No Longer Available
 | Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE Dan and Lillie Sterling Professor of Clinical Gastroenterology Chief, Division of Gastroenterology, Hepatology, and Nutrition University of Texas Health Science Center at Houston Houston, TX |
 | William D. Chey, MD, AGAF, FACG, FACP Timothy T. Nostrant Collegiate Professor of Gastroenterology Professor of Nutrition Sciences Chief, Division of Gastroenterology & Hepatology Departments of Internal Medicine and Nutritional Sciences Michigan Medicine University of Michigan Ann Arbor, MI |
 | Nicholas J. Shaheen, MD, MPH Professor of Medicine and epidemiology Chief, Division of Gastroenterology & Hepatology University of North Carolina School of Medicine Chapel Hill, NC |
The prevalence of gastroesophageal reflux disease (GERD) appears to be rising. The etiology of this increasing prevalence is multifactorial and includes effects of obesity, high calorie intake, and sedentary lifestyle. Patients with GERD and nocturnal reflux have worse quality of life than healthy individuals due to their impaired function during the day.
Despite the available treatments for GERD, unmet needs exist. These gaps in treatment include breakthrough and night-time symptoms despite using GERD agents, patient dissatisfaction with current therapies, suboptimal patient engagement and satisfaction with current therapies, and clinicians that are not adequately recognizing the unique needs within special populations of patients with GERD, especially Asian patients.1 The GERD in Asia Pacific Study (GAPS) showed that 94% of PPI-treated GERD sufferers had breakthrough symptoms and 61% at night.2
Expert faculty, in a replay of a recent national interactive and patient-centered symposium, integrate a complex patient case to demonstrate best practices, provide resources, and encourage clinicians to integrate evidence-based models to optimize clinical outcomes in GERD treatment.
- Goh KL, Choi MG, Hsu WP, et al. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific survey. J Gastroenterol Hepatol. 2014;29(12):1969-1975. PMID: 24990817.
- Chey W, Rubenstein JH. The evolving landscape in GERD: what are the issues/unmet needs and solutions?: post assessment results. Medscape Website. http://www.medscape.org/viewarticle/707669_8. Published August 27, 2009. Accessed January 26, 2015.
At the end of this CE activity, participants should be able to:
- Implement a treatment strategy with novel technologies to identify and manage breakthrough and nocturnal symptoms for patients with gastroesophageal reflux disease (GERD).
- Define and manage barriers to patient engagement and satisfaction with GERD therapies
- Recognize the metabolism differences in special populations of patients with GERD, especially Asian patients.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Evaluate a treatment strategy with novel technologies to identify and manage breakthrough and nocturnal symptoms for patients with gastroesophageal reflux disease (GERD).
- Define barriers to patient engagement and satisfaction with GERD therapies.
- Explain the metabolism differences in special populations of patients with GERD, especially Asian patients.
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region.
Gastroenterologists, physician assistants, nurse practitioners, nurses, pharmacists and other health care professionals involved in the care of patients with GERD.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners and Clinical Nurse Specialists: The content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.1 CEUs)
Universal Activity Number: 0376-0000-15-015-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST9017 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Cash has no disclosures to report.
Dr. Chey has disclosed that he has received research and grant support from Ardelyx; Asubio Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; Nestle; and Perrigo Company plc. He serves as a consultant for AstraZeneca; Ardelyx; Asubio Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; Nestle; Prometheus Laboratories Inc.; SK Biopharmaceuticals Co., Ltd.; Sucampo Pharmaceuticals, Inc.; and Takeda Pharmaceuticals North America, Inc.
Dr. Shaheen has disclosed that he has received research and grant support from Covidien; CSA Medical, Inc.; RedPath Diagnostics; Takeda Pharmaceuticals U.S. A., Inc. - All research grants to University of North Carolina
Jeffery Helfand, DO, MS (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Frances Daniel, MPH (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-061-061515-20
